摘要
细胞内钙离子浓度的增加在许多癌症特征的建立起着关键作用,包括异常增殖、迁移、入侵、抗凋亡和抗血管再生。钙离子进入失调是一种最微妙的机制,通过这种机制癌细胞消灭同行并且获得自适应优势,从而在整个有机体实现肿瘤生长,血管生成和传播。组成型和激动剂诱导的钙内流可能被贮存依赖以及贮存独立钙离子进入路线介导。越来越多的证据表明,癌症细胞里不同亚型的基质互动分子(Stim)和Orai蛋白质,即Stim1,Stim2,Orai1和Orai3以这两种途径为基础。无论是Stim和Orai蛋白的表达还是活动都已被链接到在许多实体瘤肿瘤表型的发生和维持上 ,包括前列腺癌、乳腺癌、肾,食管,皮肤,大脑,大肠癌,肺和肝等器官癌症。这里,我们调查现有数据以支持Stim和Orai在肿瘤发生关系的参与度并针对癌症患者提供基本原理。此外,我们总结了新的药理学鉴定工具方面的进步,这些工具已成功用于临床医疗。
关键词: Stim
Current Medicinal Chemistry
Title:Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy
Volume: 23 Issue: 30
Author(s): Francesco Moccia, Estella Zuccolo, Valentina Poletto, Ilaria Turin, Germano Guerra, Paolo Pedrazzoli, Vittorio Rosti and Camillo Porta, Daniela Montagna
Affiliation:
关键词: Stim
摘要: An increase in intracellular Ca2+ concentration plays a key role in the establishment of many cancer hallmarks, including aberrant proliferation, migration, invasion, resistance to apoptosis and angiogenesis. The dysregulation of Ca2+ entry is one of the most subtle mechanisms by which cancer cells overwhelm their normal counterparts and gain the adaptive advantages that result in tumour growth, vascularisation and dissemination throughout the organism. Both constitutive and agonist-induced Ca2+ influx may be mediated by store-dependent as well as store-independent Ca2+ entry routes. A growing body of evidences have shown that different isoforms of Stromal Interaction Molecules (Stim1) and Orai proteins, i.e. Stim1, Stim2, Orai1 and Orai3, underlie both pathways in cancer cells. The alteration in either the expression or the activity of Stim and Orai proteins has been linked to the onset and maintenance of tumour phenotype in many solid malignancies, including prostate, breast, kidney, esophageal, skin, brain, colorectal, lung and liver cancers. Herein, we survey the existing data in support of Stim and Orai involvement in tumourigenesis and provide the rationale to target them in cancer patients. Besides, we summarize the most recent advances in the identification of novel pharmacological tools that could be successfully used in clinical therapy.
Export Options
About this article
Cite this article as:
Francesco Moccia, Estella Zuccolo, Valentina Poletto, Ilaria Turin, Germano Guerra, Paolo Pedrazzoli, Vittorio Rosti and Camillo Porta, Daniela Montagna , Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer Therapy, Current Medicinal Chemistry 2016; 23 (30) . https://dx.doi.org/10.2174/0929867323666160607111220
DOI https://dx.doi.org/10.2174/0929867323666160607111220 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-a] Pyridine Derivatives
Medicinal Chemistry Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Stem Cell Guardians – Old and New Perspectives in LSC Biology
Current Drug Targets Negative Regulation of NEDD8 Conjugation Pathway by Novel Molecules and Agents for Anticancer Therapy
Current Pharmaceutical Design Malignancy in Common Variable Immune Deficiency: Report of Two Rare Cases of Gastrointestinal Malignancy and a Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Selection of Reprogramming Factors of Induced Pluripotent Stem Cells Based on the Protein Interaction Network and Functional Profiles
Protein & Peptide Letters Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy The Design and Synthesis of Novel Phenothiazine Derivatives as Potential Cytotoxic Agents
Letters in Drug Design & Discovery Intracellular Trafficking of Plasmids for Gene Therapy: Mechanisms of Cytoplasmic Movement and Nuclear Import
Current Gene Therapy Implications of Somatic Mutations in the AML1/RUNX1 Gene in Myelodysplastic Syndrome (MDS): Future Molecular Therapeutic Directions for MDS
Current Cancer Drug Targets Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Amygdalin Decreases Adhesion and Migration of MDA-MB-231 and MCF-7 Breast Cancer Cell Lines
Current Molecular Pharmacology The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Current Drug Targets New Strategies in the Chemotherapy of Leukemia: Eradicating Cancer Stem Cells in Chronic Myeloid Leukemia
Current Cancer Drug Targets CB 1954: From the Walker Tumor to NQO2 and VDEPT
Current Pharmaceutical Design Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Biogenesis Inhibitors for Anticancer Therapy: A Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery